Janus Henderson Group
YMAB

Janus Henderson Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Janus Henderson Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,300
Closed -$128K – 2558
2024
Q4 		$128K Hold
16,300
– – ﹤0.01% 2497
2024
Q3 		$214K Hold
16,300
– – ﹤0.01% 2409
2024
Q2 		$197K Buy
+16,300
New +$220K ﹤0.01% 2392

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Janus Henderson Group's YMAB Position: Q1 2025 in Review

Janus Henderson Group sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 16,300 shares — an estimated $128K sold.

Janus Henderson Group first reported a position in YMAB in Q2 2024 and held it in 3 quarters. The position peaked at $214K in Q3 2024. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Janus Henderson Group reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Janus Henderson Group sold 16,300 Y-mAbs Therapeutics shares in Q1 2025, an estimated $128K.
  • Janus Henderson Group first reported a position in Y-mAbs Therapeutics in Q2 2024 and held it in 3 quarters.
  • Janus Henderson Group's Y-mAbs Therapeutics position peaked at $214K in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Janus Henderson Group's 13F filing for Q1 2025, filed 15 May 2025.